Abstract
Oxidative stress and inflammatory cytokines such as monocyte chemoattractant protein 1 (MCP-1), TGF-beta, and IL-2 are supposed to play crucial roles in the pathogenesis of insulin resistance (IR). Tranilast is an anti-allergic drug which exerts anti-inflammatory and anti-angiogenesis effects through inhibition of expression of MCP-1, TGF-beta, and antigen-induced IL-2 lymphocyte responsiveness. It also possesses a certain antioxidant activity. Considering the above facts and in view of its safety, tranilast may prove invaluable in the treatment of IR.
MeSH terms
-
Adipose Tissue / drug effects
-
Adipose Tissue / metabolism
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antioxidants / pharmacology
-
Antioxidants / therapeutic use
-
Chemokine CCL2 / biosynthesis
-
Chemokine CCL2 / genetics
-
Cytokines / physiology
-
Depression, Chemical
-
Diabetes Mellitus, Type 2 / prevention & control
-
Gene Expression Regulation / drug effects
-
Humans
-
Insulin Resistance* / physiology
-
Intercellular Adhesion Molecule-1 / biosynthesis
-
Intercellular Adhesion Molecule-1 / genetics
-
Interleukin-2 / antagonists & inhibitors
-
Interleukin-2 / pharmacology
-
Models, Biological
-
Oxidative Stress
-
Transforming Growth Factor beta / biosynthesis
-
Transforming Growth Factor beta / genetics
-
ortho-Aminobenzoates / pharmacology
-
ortho-Aminobenzoates / therapeutic use*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antioxidants
-
CCL2 protein, human
-
Chemokine CCL2
-
Cytokines
-
Interleukin-2
-
Transforming Growth Factor beta
-
ortho-Aminobenzoates
-
Intercellular Adhesion Molecule-1
-
tranilast